Value of metastin receptor immunohistochemistry in predicting metastasis after radical nephrectomy for pT1 clear cell renal cell carcinoma

Clinical and Experimental Metastasis

Volumn 30, Issue 5, 2013, Pages 607-614

  Shoji, Sunao ^a   Nakano, Mayura ^a   Tomonaga, Tetsuro ^a   Kim, Hakushi ^a   Hanai, Kazuya ^b   Usui, Yukio ^b   Nagata, Yoshihiro ^a   Miyazawa, Masak ^b   Sato, Haruhiro ^b   Tang, Xian Yang ^c   Osamura, Yoshiyuki Robert ^d   Uchida, Toyoaki ^a   Terachi, Toshiro ^b   Takeya, Koichi ^e  

^a TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^e TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Immunohistochemistry; Metastasis; Metastin receptor; Renal cell carcinoma

Indexed keywords

G PROTEIN COUPLED RECEPTOR 54; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS FREE SURVIVAL; NEPHRECTOMY; PREDICTION; PREDICTIVE VALUE; RADICAL RESECTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; RECEPTORS, G-PROTEIN-COUPLED; TUMOR MARKERS, BIOLOGICAL;

EID: 84878560727     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9564-3     Document Type: Article

References (32)

1. West A, Vojta PJ, Welch DR, Weissman BE (1998) Chromosome localization and genomic structure of the KiSS-1 metastasis suppressor gene (KISS1). Genomics 54:145-148
2. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y, Ishibashi Y, Watanabe T, Asada M, Yamada T, Suenaga M, Kitada C, Usuki S, Kurokawa T, Onda H, Nishimura O, Fujino M (2001) Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 411:613-617
3. Shoji S, Tang XY, Sato H, Usui Y, Uchida T, Terachi T (2010) Metastin has potential as a suitable biomarker and novel effective therapy for cancer metastasis (Review). Oncol Lett 1:783-788
4. Roseweir AK, Millar RP (2009) The role of kisspeptin in the control of gonadotrophin secretion. Hum Reprod Update 15:203-212
5. Shoji S, Tang XY, Umemura S, Itoh J, Takekoshi S, Shima M, Usui Y, Nagata Y, Uchida T, Osamura RY, Terachi T (2009) Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor. Eur Urol 55:441-449
6. Chen Y, Yusenko MV, Kovacs G (2011) Lack of KiSS1R expression is associated with rapid progression of conventional renal cell carcinoma. J Pathol 223:46-53
7. Wallen EM, Pruthi RS, Joyce GF, Wise M (2007) Urologic diseases in America project. Kidney cancer. J Urol 177:2006-2018
8. Levy DA, Slaton JW, Swanson DA, Dinney CP (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159:1163-1167
9. Ljungberg B, Alamdari FI, Rasmuson T, Roos G (1999) Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 84:405-411
10. Lam JS, Leppert JT, Figlin RA, Belldegrun AS (2005) Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep 6:7-18
11. Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H (2002) Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology 59:532-537
12. Adamy A, Chong KT, Chade D, Costaras J, Russo G, Kaag MG, Bernstein M, Motzer RJ, Russo P (2011) Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 185:433-438
13. Edge SB, Compton CC (2005) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 173:918-921
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 5:649-655
15. Uzzo RG, Novick AC (2003) Surveillance strategies following surgery for renal cell carcinoma. In: Belldegrum A, Ritchie AWS, Figlin RA, Oliver RTD, Vaughan ED Jr (eds) Renal and adrenal tumors: biology and management. Oxford University Press, Oxford, pp 324-330
16. Stephenson AJ, Chetner MP, Rourke K, Gleave ME, Signaevsky M, Palmer B, Kuan J, Brock GB, Tanguay S (2004) Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172:58-62
17. Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55:851-863
18. Choisy-Rossi C, Yonish-Rouach E (1998) Apoptosis and the cell cycle: the p53 connection. Cell Death Differ 5:129-131
19. Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C (2004) Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63:651-655
20. Cho DS, Joo HJ, Oh DK, Kang JH, Kim YS, Lee KB, Kim SJ (2005) Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J 46:133-140
21. Kankuri M, Söderström KO, Pelliniemi TT, Vahlberg T, Pyrhönen S, Salminen E (2006) The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Res 26:3825-3833
22. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715
23. Kankuri-Tammilehto MK, Söderström KO, Pelliniemi TT, Vahlberg T, Pyrhönen SO, Salminen EK (2010) Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Res 30:3023-3330
24. Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90:1529-1536
25. Pruthi RS, Derksen E, Gaston K (2003) Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 169:2352-2359
26. Potter C, Harris AL (2004) Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3:164-167
27. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T (2007) Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100:556-560
28. Sakai I, Miyake H, Takenaka A, Fujisawa M (2009) Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. BJU Int 104:942-946
29. Leroy X, Zerimech F, Zini L, Copin MC, Buisine MP, Gosselin B, Aubert JP, Porchet N (2002) MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. Am J Clin Pathol 118:47-51
30. O-Charoenrat P, Rhys-Evans P, Modjtahedi H, Court W, Box G, Eccles S (2000) Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer 86:307-317
31. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J (1995) Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255-265
32. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M (1999) MUC1 and cancer. Biochim Biophys Acta 1455:301-313